UNIVERSITY CURRICULUM VITAE FORMAT
CURRICULUM VITAE DATE: DATE \@ "MMMM d, yyyy" August 29, 2021NAME:Amesika Nicole NyakuPRESENT TITLE: Assistant ProfessorHOME ADDRESS: 184 Harrison Ave, Jersey City, New Jersey 07304OFFICE ADDRESS: 185 South Orange, MSB I 689, Newark, New Jersey 07103TELEPHONE NUMBER/E-MAIL ADDRESS: 973-972-6214/amesika.nyaku@rutgers.eduCITIZENSHIP: USAEDUCATION:Undergraduate Graduate and ProfessionalNorthwestern UniversityEvanston, IL Bachelor of Arts (Chemistry)May 2006Graduate and ProfessionalNorthwestern UniversityChicago, ILDoctor of MedicineMay 2010Northwestern UniversityChicago, ILMaster of Science (Clinical Investigation)June 2016POSTGRADUATE TRAINING:A. Internship and ResidenciesNorthwestern Memorial HospitalInternal MedicineJuly 2010 – June 2013Northwestern Memorial HospitalInfectious DiseasesJuly 2013 – June 2015Research Fellowships:Northwestern Memorial HospitalInfectious DiseasesJuly 2015 – August 2016MILITARY: noneACADEMIC APPOINTMENTS:Department of MedicineRutgers- New Jersey Medical SchoolAssistant ProfessorAugust 2016 – present HOSPITAL APPOINTMENTS:University HospitalAttending PhysicianSeptember 2016 – presentNorthwestern Lake Forest HospitalAssociate Attending PhysicianOctober 2014 – September 2016 OTHER EMPLOYMENT OR MAJOR VISITNG APPOINTMENTS: not applicablePRIVATE PRACTICE: not applicableLICENSURE: Medical Doctor/June 2023DRUG LICENSURE:CDS: October 2023, DEA/DATA 2000 waiver: October 2023CERTIFICATION: Internal Medicine/December 2023Infectious Diseases/December 2026MEMBERSHIPS, OFFICES AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES:Infectious Diseases Society of AmericaMemberOctober 2014 - presentHIV Medicine AssociationMemberOctober 2014 – presentInternational AIDS SocietyMemberMay 2016 - presentHONORS AND AWARDS:Nomination Golden Apple Award for TeachingNominated by: Student Family Health Care CenterMarch 2018Chief Fellow, Infectious DiseasesAwarded by: Northwestern University, Feinberg School of Medicine, Department of MedicineJuly 2014Design Industries Foundation Fighting AIDS Chicago FellowAwarded by: Design Industries Foundation Fighting AIDS July 2014Outstanding Infectious Diseases Fellow Teaching AwardAwarded by: Northwestern University, Feinberg School of Medicine, Department of Medicine Division of Infectious DiseasesJuly 2014BOARDS OF DIRECTORS/TRUSTEES POSITIONS: noneSERVICE ON NATIONAL GRANT REVIEW PANELS, STUDY SECTIONS, COMMITTEES: noneSERVICE ON MAJOR COMMITTEES:International:AIDS Clinical Trial Group Antiretroviral Therapy Strategies Transformative Science Group Investigator February 2018 – February 2021Study Monitoring Committee of the AIDS Clinical Trial Group Antiretroviral Therapy Strategies Transformative Science GroupInvestigator July 2018 – presentNational: noneMedical School/University: NJMS Addiction Workgroup member July 2018 - currentHospital: Anti-Infective Subcommittee, Jan 2018 – Sept 2018Department: noneEditorial Boards: noneAdHoc ReviewerTransplant Infectious Diseases, 2016HIV Links, 2018Journal of International Antimicrobial Agents, 2019Journal of Infectious Diseases, 2020SERVICE ON GRADUATE SCHOOL COMMITTEES: noneSERVICE ON HOSPITAL COMMITTEES: Anti-Infective Subcommittee member, Jan 2018 – Aug 2018SERVICE TO THE COMMUNITY: Newark EMA Quality Management Committee Clinical Specialist, Aug 2017 – presentDMHAS Stakeholder Constituency Leadership Committee, June 2020-presentSPONSORSHIP (Primary Mentorship) OF CANDIDATES FOR POSTGRADUATE DEGREE:MastersAparna Akyar – Master of Biomedical Sciences program, Rutgers-Newark SGS 2020Topic: A Survey of Attitudes of Participants in HIV Prevention ResearchDoctoralFaith Pettyjohn – Doctoral Nursing Practice, Rutgers School of Nursing, 2020Graduate thesis project: Waitlist effects on engagement in treatment for opioid use disorder SPONSORSHIP (Primary Mentorship) OF POSTDOCTORAL FELLOWS:Louis Lerebours, MD – Addiction Medicine Fellow, Scholar, Yale REACH Program, 2020Topic: Engaging and transforming social networks to help reduce drug useTEACHING RESPONSIBILITIES: Lectures or Course Directorships:Addiction Medicine fellow didactics in core competencies (lectures each year) -2019 (2), 2020 (4), Infectious Disease fellow didactics in core competencies (lectures each year) – 2016 (2), 2017 (2), 2018 (2), 2019 (2), 2020 (3), Medicine clerkship didactics in core competencies: Infective Endocarditis (lectures each year) – 2018 (8), 2019 (8), 2020 (online)Medicine clerkship didactics in core competencies: Sexual Transmitted Infections 8/year - 2018, 2019Motivational interviewing small group preceptor – 3 hours/year - 2017, 2018Research Training (other than Primary Mentorship)Post Doctoral Fellows: ID fellowship research/clinical quality improvement supervisor 2018 – currentPre Doctoral Students: Udisa Chowdhury, Rutgers- Newark SGS2019 – 2020Topic: PrEP initiation among people who inject drugsPayal Shah, Ha Young Cho, Rutgers- Newark SGS2020 – PresentTopic: Changes in treatment retention after addition of navigators in a low barrier opioid use disorder clinic Arley Giraldo, Rutgers-NJMSScholar, Hispanic Center of Excellence2019 – PresentTopic: Demographics in a low barrier opioid use disorder clinic in an urban settingSerra Akyar, Rutgers-NJMS2019 – 2020Topic: Patient satisfaction with shared medical appointments in an urban buprenorphine clinicRichard Wolferz, Rutgers-NJMS2019 – 2020Topic: Treatment retention and engagement in OUD care with peer navigation support in an urban buprenorphine clinicCLINICAL RESPONSIBILITIES: Outpatient HIV, HIV prevention, HCV and general infectious diseases careOutpatient based addiction treatment with medications for opioid use disorderInpatient Infectious Diseases consultationInpatient General Medicine attendingGRANT SUPPORT: Principal Investigator: NJACTS, Pilot Project Grant Program, Risk Environment Analysis to Inform Overdose Education and Naloxone Distribution (OEND), 8/24/2021-8/23/2022, $50,000NIH-NIDA, K23 DA053989, Implementing Integrated Services for People with HIV and Opioid Use Disorder, 4/01/2021-03/31/20206, $1,051,885 New York University, School of Medicine, 1U01DA047982, Long-acting buprenorphine vs naltrexone opioid treatments in CJS-involved adults (EXIT-CJS), 08/01/2020-07/31/2024, $2,508,412.04Co-InvestigatorSAMHSA, 1H79 TI081510, Opioid Peer Emergency Navigation to Accessing Comprehensive Care and Engaging Specialized Services (OPEN ACCESS), 2/28/2019-2/27/2022, $1,564,554Pending: ARHQ, R01 13383695, Improving Opioid Recovery and Outcomes for Released Prisoners (co-investigator)CompletedNIH-NIAID, 2 UM1 AI069419-15, Weill Cornell Medical College – New Jersey Medical School Clinical Trials Unit, 10/1/2016-3/31/2021, $2,109,2020 (co-investigator)New Jersey DHS DMAHS, DR6464, Northern New Jersey Medication Assisted Treatment Center of Excellence, 4/1/2019-6/30/2022, $6,500,000 (co-principal investigator)Incyte - Novartis, Ruxolitinib in patients with COVID-19 associated cytokine storm (RUXCOVID), 4/27/2020-6/29/2021, $1591,879 (if enrolled), (principal investigator)NJ DHSTS, DHST20FPR014, DHSTS Federal HIV Prevention Program 2020, 1/1/2021-12/31/2021, $523,000 (physician)HRSA Ryan White HIV/AIDS Program, Award number not available, Ryan White Part A/F Emergency Relief, 3/1/2020-2/29/2021, $1,342,000 (physician)HRSA Ryan White HIV/AIDS Program, 5 H76HA28079, Ryan White Part C Outpatient EIS Program, 1/1/2021-12/31/2021 (physician)NIH-NIAID, T32 A1095207, Northwestern University Infectious Diseases Education and Science, 8/1/2014-7/31/2016 (trainee)PUBLICATIONS: Refereed Original Article in JournalTreitler PC, Bowden CF, Lloyd, J, Enich M, Nyaku AN, et al. et al. Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms. J Subst Abuse Treat 132, 108514 (2021). [epub ahead of print]Waddell EN, Springer SA, Marsch LA, Farabee, D, Schwartz PA, Nyaku A, et al. Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS). Journal of Substance Abuse Treatment 108389 (2021) doi:10.1016/j.jsat.2021.108389.Corey L, HVTN 704/HTPN 085 and HVTN 703/HPTN 081 Study Teams, et al. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. N Engl J Med 384, 1003–1014 (2021).Baden LR, COVE Study Group, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 384, 403–416 (2021).Taiwo BO, Qui?ones-Mateu ME, Smith K, Zeng L, Gulick R, Nyaku AN, et al. Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy. AIDS Res Hum Retroviruses 2020; 36:254–255. Li JZ, Sax PE, Marconi VC, Fajnzylber J, Berzins B, Nyaku AN, et al. No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial. Open Forum Infect Dis 2019; 6:ofz056. Nyaku AN, Zheng L, Gulick RM, et al. Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500?000 copies/mL: week 48 outcomes from ACTG 5353. J Antimicrob Chemother 2019; 74:1376–1380.Taiwo BO, Zheng L, Stefanescu A, Nyaku A, Bezins B, Wallis CL, et al. ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL. Clin Infect Dis. 2018 May 17;66(11):1689–97. Taiwo BO, Marconi VC, Berzins B, Moser CB, Nyaku AN, Fichtenbaum CJ, et al. Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial. Clin Infect Dis. 2018 May 17;66(11):1794–7. Morgan E, Nyaku AN, D?Aquila RT, Schneider JA. Determinants of HIV Phylogenetic Clustering in Chicago Among Young Black Men Who Have Sex With Men From the uConnect Cohort. J Acquir Immune Defic Syndr. 2017 01;75(3):265–70. Nyaku AN, Williams LM, Galvin SR. Comparison of HIV Testing Uptake in an Urban Academic Emergency Department Using Different Testing Assays and Support Systems. AIDS Patient Care STDS. 2016 Apr;30(4):166–9.Books, Monographs and Chapters: nonePatents Held: noneOther Articles (Reviews, Editorials, etc.) In Journals; Chapters; Books; other Professional CommunicationsNyaku, AN, Advances in Two-Drug Antiretroviral Regimens, HIV Specialist, 10, 20-23, 2018Nyaku, AN, Kelly, SG, & Taiwo, BO, Long-Acting Antiretrovirals: Where Are We now? Current HIV/AIDS Reports, 14, 63-71, 2017Kelly, SG, Nyaku, AN, & Taiwo, BO, Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere? Drugs, 76, 523-31, 2016PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5OeWFrdTwvQXV0aG9yPjxZZWFyPjIwMTY8L1llYXI+PFJl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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5OeWFrdTwvQXV0aG9yPjxZZWFyPjIwMTY8L1llYXI+PFJl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ADDIN EN.CITE.DATA AbstractsAkyar S, Nyaku A, et al. Patient Satisfaction with Shared Medical Appointments Among Patients with Opioid Use Disorder Attending an Urban Buprenorphine Clinic. American Academy of Addiction Psychiatry 31st Annual Meeting and Scientific Symposium, Dec 10-12, 2020.Sudyn AW, Paer JM, Kodali S, Maldonado S, Nyaku A, Swaminathan S. Linkage to Care Outcomes among Known HIV-Positive Patients at a High Prevalence Urban Hospital Emergency Department. IDWeek 2020, Sept 21-Sept 30, 2020. Abstract 962.Kodali S, Paer JM, Sudyn AW, Maldonado S, Nyaku A, Swaminathan S. The Impact of Opt-Out HIV Screening and Patient Navigator-Assisted Linkage to Care of Newly Diagnosed Persons with HIV in a High-Prevalence Emergency Department. IDWeek 2020, Sept 21-Sept 30, 2020. Abstract 968.Fabricant S, Nyaku A, Dalla-Piazza ML. Integrating buprenorphine into an urban HIV primary care practice: Outcomes on viral load suppression and opioid use. IDWeek 2020, Sept 21-Sept 30, 2020. Abstract 1025.Han MK, Bender Ignacio RA, Lopez Bernus A, Milger-Kneidinger, K, Nyaku AN, et al. RUXCOVID: a phase 3, randomized, placebo-controlled study evaluating the efficacy and safety of ruxolitinib in patients with COVID-19-associated cytokine storm (NCT04362137). AACR Virtual Meeting: COVID-19 and Cancer, July 20-22, 2020.Li J, Sax P, Marconi V, Fajnzylber J, Berzins B, Nyaku A, et al. No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial. HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow. Abstract O145.Chew D, Tejura N, Closeil G, Nyaku A, Swaminathan, S. Challenges in PrEP Implementation in an Urban Infectious Diseases Clinic with a High Background HIV Prevalence. 2018 STD Prevention Conference, August 27-30, 2018, Washington, DC.Taiwo, BO, Zheng, L, Nyaku, AN, et al.; ACTG A5353: a pilot study of dolutegravir (DTG) + lamivudine (3TC) for initial treatment of HIV-1-infected participants with HIV-1 RNA < 500,000 copies/mL.; Presented at IAS, 2017; MOAB0107LBTaiwo, BO, Marconi, V, Berzins, B, Janulis, P, Nyaku, AN, et al.; Dolutegravir plus lamivudine maintains HIV-1 suppression through week 48 in a pilot randomized trial, Presented at EACS, 2017; PE8/5Nyaku, A; Morgan, E; Penugonda, S; Galvin, S; D’Aquila, R; Schneider, J; Molecular Correlates of Young Black Men who have Sex with Men Sexual Networks; Presented at Third Coast CFAR Symposium, 2016Morgan, E; Nyaku, A; D’Aquila, R; Schneider, J; Using phylogenetics of HIV to inform prevention among young men who have sex with men in Chicago; Presented at AIDS, 2016; THAX0103Shannon, G and Nyaku, A; Comparison of HIV Testing Uptake in an Urban Academic Emergency Department Using Different Testing Assays and Support Systems; Presented at AIDS, 2014; WEPE027 Reports: noneMEDIAPeriodicalsOp-Ed: 3 steps to save lives as NJ’s opioid addictions rise, by Erin Zerbo and Amesika Nyaku. The Star-Ledger, , September 30, 2020.Patients and Psychiatrists Alike Face Hurdles in Buprenorphine Prescribing, Psychiatric News, November 15, 2019, 54(22) the Frontlines of the Opioid Epidemic, Pulse Magazine, Fall 2019 Prevention – Nothing About Us Without US!, HOT97, July 13, 2017 Literacy Pertaining to COVID-19 – Elmwood Health Ministry - May 21st, 2021COVID-19 Vaccine: Facts & Myths – The Newark Public Library – May 4th, 2021Inclusion and Diversity in Clinical Trials: Actionable Steps to Drive Lasting Change – Duke Clinical Research Institute - April 28th, 2021Abolish the Drug War – Seton Hall University – March 30th, 2021COVID-19 & Vaccines -Greater Newark Healthcare Coalition- March 23rd, 2021New Jersey Black Legislative Caucus/ New Jersey Medical Association Colloquium – January 21, 2021Morristownship Town Hall on COVID-19 Vaccines – January 19, 2021 NJ Let’s Get Vaccinated -New Jersey Department of Health - January 13, 2021African Community COVID-19 Vaccine Awareness: What you Should Know – Dec 29, 2020Continuing the Conversation about COVID-19 Clinical Trials, hosted by University Hospital, NJ, October 12, 2020Conspiracies & COVID in Communities of Color, hosted by Rutgers New Jersey Medical School Clinical Research Center, October 1, 2020Pros & Cons of Africans and African Americans Participating in the COVID-19 Vaccine Clinical Trial, hosted by Skadek Network International, INC, September 24, 2020PRESENTIONS:Scientific (Basic Science): noneProfessional (Clinical):Integrating Substance Use Treatment in Primary Clinical Setting. October 17, 2020. Northeast/Caribbean AIDS Education & Training Program.U=U and PrEP: tools for ending the HIV epidemic. December 20, 2019. Rutgers NJ Project ECHO.Updates on HIV prevention. November 27, 2019. Rutgers New Jersey Medical School. Department of Medicine Internal Residents.Treating Patients with Opioid Use Disorders Outside of Addiction Clinics. November 26, 2019. Rutgers New Jersey Medical School Internal Medicine Grand Rounds.From Bending the Curve to Ending the Epidemic: the NYC and NJ Experience. November 1, 2019. SE AETC and TN AETC 22nd Annual SymposiumMedical Comorbidities. July 26, 2019. American Society of Addiction Medicine Review Course.Dolutegravir plus lamivudine for initial treatment of HIV-1 infected participants with HIV-1 RNA < 500,000 copies/mL: week 48 outcomes from ACTG 5353. June 18, 2019. AIDS Clinical Trials Group Network Meeting, 2019.Updates on HIV Prevention. March 22, 2019. ACP New Jersey Chapter Annual Scientific Meeting 2019.Fungal infections in hepatology February 27, 2019. Rutgers New Jersey Medical School. Division of Gastroenterology/Hepatology.Bending the curve –utilizing treatment as prevention to end the HIV/AIDS epidemic. November 28, 2018. World AIDS day 2018. Rutgers New Jersey Medical School.Infections in end stage liver disease. January 24, 2018. Rutgers New Jersey Medical School. Division of Gastroenterology/Hepatology.HIV prevention. Rutgers New Jersey Medical School. Preventive Medicine Educational Conference May 7, 2018.“Closing the Gap” Health Symposium. Lunch with the Expert. Newark Community Health Advisory Council. April 11, 2018HIV in the ED. Crozer-Chester Emergency Medicine Residency Grand Rounds, 2016Long-acting Antiretrovirals: Promise and Pitfalls. AIDS Clinical Trials Group Network Meeting, 2016Molecular Surveillance of HIV in Young Black Men who have Sex with Men in Chicago: from the bench to public health and prevention. Northwestern University Feinberg School of Medicine Infectious Diseases Research Symposium, 2016 ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- new jersey commission on spinal cord research
- university curriculum vitae format
- the state university of new jersey
- new pathways to teaching in new jersey
- instructions for claiming unemployment benefits
- specialization in teaching esl in higher education at new
- njcu travel voucher new jersey city university
- overview mccc
- university of medicine and dentistry of new jersey
Related searches
- curriculum vitae template word document
- curriculum vitae finance manager sample
- curriculum vitae format in word
- curriculum vitae sample doc
- curriculum vitae sample pdf
- curriculum vitae samples for teachers
- curriculum vitae template free download
- curriculum vitae template word download
- nursing curriculum vitae template pdf
- best curriculum vitae format
- curriculum vitae en francais modele
- curriculum vitae examples word